Journey Medical Corporation announced that payer coverage for its rosacea treatment, Emrosi™, has significantly increased from 29% to 65% of commercial lives in the U.S. since May 2025, representing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback